Kezar Life Sciences, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDKezar Life Sciences, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 82), indicating clear outperformance against the broad market. Earnings growth of 66% provides fundamental context to the price action. Investors should exercise caution due to high volatility (67% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $7.32 | -0.48% | BELOW |
| 50 SMA | $7.14 | +2.16% | ABOVE |
| 100 SMA | $6.72 | +8.44% | ABOVE |
| 150 SMA | $6.43 | +13.39% | ABOVE |
| 200 SMA | $5.81 | +25.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KZR in an uptrend right now?
KZR has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, KZR is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is KZR overbought or oversold?
KZR's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.
Is KZR outperforming the market?
KZR has a Relative Strength (RS) Rating of 82 out of 99. Yes, KZR is a market leader, outperforming 82% of all stocks over the past 12 months.
Where is KZR in its 52-week range?
KZR is trading at $7.29, which is 97% of its 52-week high ($7.55) and 94% above its 52-week low ($3.53).
How volatile is KZR?
KZR has a Beta of 0.70 and 52-week volatility of 67%. It's less volatile than the S&P 500 - generally more stable.